Harshini Neelakantan
Executive Director - Research & Development Ridgeline Therapeutics
Dr. Neelakantan is a co-inventor of Ridgeline Therapeutics’ founding technology and has supported the company’s therapeutic development programs for over a decade. Her expertise spans early discovery and lead optimization, translational in vivo validation, and IND-enabling preclinical development across metabolic (obesity), neurological (acute and chronic pain), neuropsychiatric (addiction), and musculoskeletal diseases. She serves as an elected Councilor and board member of the American Society for Pharmacology and Experimental Therapeutics (ASPET) and is a co-founder of ASPET’s Industry Science Committee.
Seminars
Wednesday 9th December 2026
Preserving Muscle Strength to Maximize the Impact of GLP-1s in Obesity Management
11:30 am
- Combining a novel oral therapy with GLP-1s to deliver additional weight loss while improving muscle strength throughout treatment
- Targeting the underlying drivers of muscle regeneration to support healthy weight loss and functional independence
- Enhancing muscle quality and repair alongside weight reduction to improve long-term outcomes for older adults with obesity
